Clinical trials: Mild Asthma
Asthma, Bronchial
A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)
A study to evaluate MK0476 and Fluticasone to control asthma in patients with mild persistent asthma.
- Trial name
- NCT00489346
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 1 Year, Comparator : fluticasone propionate / Duration of Treatment: 1 Year
- Volunteers
- 994 people
- Sponsor
- Organon and Co
Asthma
Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma
This study will evaluate the safety and efficacy of omalizumab against asthma attacks in mild to moderate allergic asthma
- Trial name
- NCT00546143
- Testing
- Omalizumab
- Where
- 5 sites in Germany, South Africa
- Volunteers
- 32 people
- Sponsor
- Novartis
Asthma
Linear Growth Study (0476-097)(COMPLETED)
The purpose of this study is to compare the effect of montelukast with placebo and beclomethasone on the average rate of linear growth over a period of 56 weeks in children with mild asthma.
- Trial name
- NCT00395408
- Testing
- MK0476, montelukast sodium / Duration of Treatment : 56 Weeks, Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks
- Volunteers
- 360 people
- Sponsor
- Organon and Co
Asthma
A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.
This study is the second Phase-II trial analyzing efficacy outcomes of PBF-680 in asthmatic subjects, following the supportive data from the proof-of-concept trial on the effect of PBF-680 on airway hyperresponsiveness to…
- Trial name
- NCT02635945
- Testing
- PBF-680
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Palobiofarma SL
Asthma
Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma
This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma.
- Trial name
- TRAILHEAD (NCT04673630)
- Testing
- Tezepelumab
- Where
- 6 sites in Hungary, South Africa and 1 more
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Atopic Dermatitis, Psoriasis
Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma
This Phase 1 study will investigate the safety and tolerability of EDP1867 in healthy volunteers, participants with atopic dermatitis, and, optionally, in participants with psoriasis and/or asthma.
- Conditions
- Atopic Dermatitis, Psoriasis, Asthma
- Trial name
- NCT04927195
- Testing
- EDP1867
- Where
- 7 sites in United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Evelo Biosciences, Inc.
Health Adults, Asthma
Study of HXN-1013 in Healthy Participants and Participants With Mild-to-Moderate Asthma
This is a Phase I, randomized, double-blind, placebo-controlled, single ascending dose study evaluating HXN-1013 in healthy participants and participants with mild-to-moderate asthma.
- Trial name
- NCT07900568
- Testing
- HXN-1013
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Helixon Biotechnology (Suzhou) Co., Ltd
Asthma
Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.
People with asthma suffer from breathlessness because the small tubes (bronchioles) that carry air in and out of the lungs become inflamed and narrow.
- Trial name
- NCT01400906
- Testing
- 100 micrograms Fluticasone propionate, 500 micrograms Fluticasone propionate, lactose powder
- Where
- 2 sites in Belgium, United Kingdom
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy, Safety and Pharmacokinetics of QAV680 in Asthma Patients
This study aims to study the efficacy (as measured by change in FEV1) and safety of two-week administration of oral QAV680 in the treatment of patients with asthma.'
- Trial name
- NCT00814216
- Testing
- QAV680, Fluticasone Propionate
- Where
- 7 sites in Germany, India
- Volunteers
- 37 people
- Sponsor
- Novartis
Asthma
Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics
A new formulation of Fluticasone propionate/Salmeterol comparing a lower dose of fluticasone propionate and salmeterol was compared with concurrent administration of fluticasone propionate and salmeterol.
- Trial name
- NCT00364442
- Testing
- fluticasone propionate/salmeterol
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate…
- Conditions
- Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis, House Dust Mite Allergy, Pollen Allergy
- Trial name
- NCT04874714
- Testing
- MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000)
- Where
- 13 sites in Spain
- Volunteers
- 18 people
- Sponsor
- Inmunotek S.L.
Asthma Bronchiale
Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma
Open, parallel group design. The study has a screening phase and a 12 week treatment phase. Subjects will be randomised to treatment in a 1:1 ration.
- Trial name
- NCT00476073
- Testing
- FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)
- Where
- United Kingdom
- Volunteers
- 228 people
- Sponsor
- Mundipharma Research Limited
Asthma
Study With GW274150 In Patients With Mild Asthma
This is a study investigating whether 14 days of dosing with GW274150 has a beneficial effect on a model of asthma type inflammation called the allergen-induced late asthmatic response.
- Trial name
- NCT00273013
- Testing
- GW274150, Singulair
- Where
- 2 sites in United Kingdom
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Mild Allergic Asthma
Safety, Tolerability and Clinical Activity of ASM-024 in Subjects With Mild Allergic Asthma
The study will assess the safety, tolerability and clinical activity of ASM-024 in subjects with mild allergic asthma.
- Trial name
- NCT01092403
- Testing
- ASM-024
- Where
- 3 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Asmacure Ltée
Asthma
Specific Use-Result of Spiriva Respimat® in Asthmatics
The study objective is to investigate the safety and effectiveness of Spiriva Respimat in patients with mild to moderate persistent asthma under real-world use
- Trial name
- NCT03188120
- Testing
- Spiriva Respimat
- Where
- Japan
- Volunteers
- 193 people
- Sponsor
- Boehringer Ingelheim
Asthma
Effect of the GSK2245035 on the Allergen-induced Asthmatic Response
This study will assess whether Toll like receptor 7 (TLR7)-mediated pharmacology, with intranasal (i.n.) GSK2245035 20 nanogram (ng) administered weekly for a period of 8 weeks, will lead to reduced allergic reactivity in the…
- Trial name
- NCT02833974
- Testing
- GSK2245035 Nasal Spray Solution
- Where
- 6 sites in Germany, United Kingdom
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
Asthma
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
- Trial name
- NCT07241546
- Testing
- ARO-RAGE
- Where
- 6 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Arrowhead Pharmaceuticals
Asthma
A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety, and tolerability of huMAb OX40L administered to patients by IV infusion for the treatment of…
- Trial name
- NCT00983658
- Testing
- huMAb OX40L
- Volunteers
- 29 people
- Sponsor
- Genentech, Inc.
Asthma
Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients
This study will evaluate the efficacy, safety and tolerability of two dosages of a new drug TPI ASM8 administered by inhalation for 14 days to mild to moderate asthmatic patients, aged between 18-65, non-smokers .
- Trial name
- NCT00402948
- Testing
- TPI ASM8, ASM8
- Where
- 10 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Syntara
Asthma
Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma
This is a randomized, double-blind, single-dose, placebo-controlled, 5-period, 5-treatment, crossover, multi-center study to assess the bronchodilatory effect and safety of 2 dose levels of Albuterol Sulfate Pressurized…
- Trial name
- NCT03364608
- Testing
- AS MDI 90 μg, AS MDI 180 µg, Proventil 90 μg
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- AstraZeneca